ArticleMaxillofacial plastic and reconstructive surgery2021
The effect of 4-hexylresorinol administration on NAD+ level and SIRT activity in Saos-2 cells.
Article in Maxillofacial plastic and reconstructive surgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 8 citations in OpenAlex.
- 4-Hexylresorcinol Attenuates Ethanol-Induced Hepatic and Pancreatic Injury by Modulating Metabolic Dysfunction and Endoplasmic Reticulum Stress.Biomedicines · 2026Article
- 4-Hexylresorcinol Enhances Glut4 Expression and Glucose Homeostasis via AMPK Activation and Histone H3 Acetylation.International journal of molecular sciences · 2024Article
- Effects of 4-hexylresorcinol on facial skeletal development in growing rats: Considerations for diabetes.Korean journal of orthodontics · 2023Article
- Administration of 4‑hexylresorcinol increases p53‑mediated transcriptional activity in oral cancer cells with the p53 mutation.Oncology reports · 2022Article
- 4-Hexylresorcinol: pharmacologic chaperone and its application for wound healing.Maxillofacial plastic and reconstructive surgery · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
background4-hexylresorcinol (4HR) has been shown to have anti-oxidant activity similar to that of resveratrol. As resveratrol increases sirtuin (SIRT) activity, 4HR might behave similarly to resveratrol.
methodIn this study, the expression levels of SIRT1, SIRT3, and SIRT6 were evaluated after 4HR administration (1-100 μM). As NAD+ is a substrate for SIRTs, its levels with SIRT activity were also studied.
resultsIn the results, SIRT3 (100 μM at 24 h) and SIRT6 (1-100 μM at 24 h and 10 μM at 8 h) were shown to have significantly higher expression levels compared to untreated control (p < 0.05). Pan-SIRT activity and the NAD+ level was significantly increased compared to that of the untreated control (p < 0.05; 10 and 100 μM at 24 h).
conclusion4HR administration increased SIRT activity and the NAD+ level in Saos-2 cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.